Why the study?
Does losartan improve haemodynamics and is it well tolerated in heart failure models and patients?
Does losartan improve haemodynamics and is it well tolerated in heart failure models and patients?
Losartan provides haemodynamic benefits and is well tolerated in heart failure, supporting its potential clinical utility.
Answers are grounded in this paper and cite their sources.
May support losartan evaluation in heart failure; leaves open guideline integration pending randomized outcome trials.
Losartan potassium (Cozaar) is an angiotensin II receptor antagonist (AT1 selective) which has undergone extensive clinical trials for the treatment of hypertension. This literature survey will review some of the pre-clinical findings with losartan in models of heart failure, and where appropriate, we will compare the haemodynamic findings in animals with similar studies completed in patients. The major conclusion from these trials is that losartan has clear haemodynamic benefits in patients in heart failure and that the drug appears to be well tolerated, with a low incidence of adverse experiences related to impaired renal function.
No takes yet. Share an insight, caveat, or question.
Sweet et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: